Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial
Gerhardt Attard, Matthew R Sydes, Malcolm D Mason, Noel W Clarke, Daniel Aebersold, Johann S de Bono, David P Dearnaley, Chris C Parker, Alastair W S Ritchie, J Martin Russell, George Thalmann, Estelle Cassoly, Robin Millman, David Matheson, Francesca Schiavone, Melissa R Spears, Mahesh K B Parmar, Nicholas D James, Gerhardt Attard, Matthew R Sydes, Malcolm D Mason, Noel W Clarke, Daniel Aebersold, Johann S de Bono, David P Dearnaley, Chris C Parker, Alastair W S Ritchie, J Martin Russell, George Thalmann, Estelle Cassoly, Robin Millman, David Matheson, Francesca Schiavone, Melissa R Spears, Mahesh K B Parmar, Nicholas D James
Abstract
There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.
Trial registration: ClinicalTrials.gov NCT00268476.
Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Source: PubMed